Patent Grant
10524685
The disclosure of the present application relates generally to medical diagnostics and treatment equipment, and in particular, to devices, systems, and methods for measuring luminal cross-sectional area of blood vessels, heart valves and other hollow visceral organs.
Coronary Heart Disease
Coronary heart disease is caused by atherosclerotic narrowing of the coronary arteries. It is likely to produce angina pectoris, heart attack or both. Coronary heart disease caused 466,101 deaths in USA in 1997 and is the single leading cause of death in America today. Approximately, 12 million people alive today have a history of heart attack, angina pectoris or both. The break down for males and females is 49% and 51%, respectively. This year, an estimated 1.1 million Americans will have a new or recurrent coronary attack, and more than 40% of the people experiencing these attacks will die as a result. About 225,000 people a year die of coronary attack without being hospitalized. These are sudden deaths caused by cardiac arrest, usually resulting from ventricular fibrillation. More than 400,000 Americans and 800,000 patients world-wide undergo a non-surgical coronary artery interventional procedure each year. Although only introduced in the 1990s, in some laboratories intra-coronary stents are used in 90% of these patients.
Stents increase minimal coronary lumen diameter to a greater degree than percutaneous transluminal coronary angioplasty (PTCA) alone according to the results of two randomized trials using the Palmaz-Schatz stent. These trials compared two initial treatment strategies: stenting alone and PTCA with “stent backup” if needed. In the Stent Restenosis Study (STRESS) trial, there was a significant difference in successful angiographic outcome in favor of stenting (96.1% vs. 89.6%).
Intravascular Ultrasound
Currently intravascular ultrasound is the method of choice to determine the true diameter of the diseased vessel in order to size the stent correctly. The term “vessel,” as used herein, refers generally to any hollow, tubular, or luminal organ, area, or space within a body. The tomographic orientation of ultrasound enables visualization of the full 360° circumference of the vessel wall and permits direct measurements of lumen dimensions, including minimal and maximal diameter and cross-sectional area. Information from ultrasound is combined with that obtained by angiography. Because of the latticed characteristics of stents, radiographic contrast material can surround the stent, producing an angiographic appearance of a large lumen, even when the stent struts are not in full contact with the vessel wall. A large observational ultrasound study after angio-graphically guided stent deployment revealed an average residual plaque area of 51% in a comparison of minimal stent diameter with reference segment diameter, and incomplete wall apposition was frequently observed. In this cohort, additional balloon inflations resulted in a final average residual plaque area of 34%, even though the final angiographic percent stenosis was negative (20.7%). These investigators used ultrasound to guide deployment.
However, using intravascular ultrasound as mentioned above requires a first step of advancement of an ultrasound catheter and then withdrawal of the ultrasound catheter before coronary angioplasty thereby adding additional time to the stent procedure. Furthermore, it requires an ultrasound machine. This adds significant cost and time and more risk to the procedure.
Aortic Stenosis
Aortic Stenosis (AS) is one of the major reasons for valve replacements in adult. AS occurs when the aortic valve orifice narrows secondary to valve degeneration. The aortic valve area is reduced to one fourth of its normal size before it shows a hemodynamic effect. Because the area of the normal adult valve orifice is typically 3.0 to 4.0 cm2, an area 0.75-1.0 cm2 is usually not considered severe AS. When stenosis is severe and cardiac output is normal, the mean trans-valvular pressure gradient is generally >50 mmHg. Some patients with severe AS remain asymptomatic, whereas others with only moderate stenosis develop symptoms. Therapeutic decisions, particularly those related to corrective surgery, are based largely on the presence or absence of symptoms.
The natural history of AS in the adult consists of a prolonged latent period in which morbidity and mortality are very low. The rate of progression of the stenotic lesion has been estimated in a variety of hemodynamic studies performed largely in patients with moderate AS. Cardiac catheterization and Doppler echocardiographic studies indicate that some patients exhibit a decrease in valve area of 0.1-0.3 cm2 per year; the average rate of change is 0.12 cm2 per year. The systolic pressure gradient across the valve may increase by as much as 10 to 15 mmHg per year. However, more than half of the reported patients showed little or no progression over a 3-9 year period. Although it appears that progression of AS can be more rapid in patients with degenerative calcific disease than in those with congenital or rheumatic disease, it is not possible to predict the rate of progression in an individual patient.
Eventually, symptoms of angina, syncope, or heart failure develop after a long latent period, and the outlook changes dramatically. After onset of symptoms, average survival is <2-3 years. Thus, the development of symptoms identifies a critical point in the natural history of AS.
Many asymptomatic patients with severe AS develop symptoms within a few years and require surgery. The incidence of angina, dyspnea, or syncope in asymptomatic patients with Doppler outflow velocities of 4 m/s has been reported to be as high as 38% after 2 years and 79% after 3 years. Therefore, patients with severe AS require careful monitoring for development of symptoms and progressive disease.
Indications for Cardiac Catheterization
In patients with AS, the indications for cardiac catheterization and angiography are to assess the coronary circulation (to confirm the absence of coronary artery disease) and to confirm or clarify the clinical diagnosis of AS severity. If echocardiographic data are typical of severe isolated. AS, coronary angiography may be all that is needed before aortic valve replacement (AVR). Complete left- and right-heart catheterization may be necessary to assess the hemodynamic severity of AS if there is a discrepancy between clinical and echocardiographic data or evidence of associated valvular or congenital disease or pulmonary hypertension.
The pressure gradient across a stenotic valve is related to the valve orifice area and transvalvular flow through Bernoulli's principle. Thus, in the presence of depressed cardiac output, relatively low pressure gradients are frequently obtained in patients with severe AS. On the other hand, during exercise or other high-flow states, systolic gradients can be measured in minimally stenotic valves. For these reasons, complete assessment of AS requires (1) measurement of transvalvular flow, (2) determination of the transvalvular pressure gradient, and (3) calculation of the effective valve area. Careful attention to detail with accurate measurements of pressure and flow is important, especially in patients with low cardiac output or a low transvalvular pressure gradient.
Problems with Current Aortic Valve Area Measurements
Patients with severe AS and low cardiac output are often present with only modest transvalvular pressure gradients (i.e., <30 mmHg). Such patients can be difficult to distinguish from those with low cardiac output and only mild to moderate AS. In both situations, the low-flow state and low pressure gradient contribute to a calculated effective valve area that can meet criteria for severe AS. The standard valve area formula (simplified Hakki formula which is valve area=cardiac output/[pressure gradient]1/2) is less accurate and is known to underestimate the valve area in low-flow states; under such conditions, it should be interpreted with caution. Although valve resistance is less sensitive to flow than valve area, resistance calculations have not been proved to be substantially better than valve area calculations.
In patients with low gradient stenosis and what appears to be moderate to severe AS, it may be useful to determine the transvalvular pressure gradient and calculate valve area and resistance during a baseline state and again during exercise or pharmacological (i.e., dobutamine infusion) stress. Patients who do not have true, anatomically severe stenosis exhibit an increase in the valve area during an increase in cardiac output. In patients with severe AS, these changes may result in a calculated valve area that is higher than the baseline calculation but that remains in the severe range, whereas in patients without severe AS, the calculated valve area will fall outside the severe range with administration of dobutamine and indicate that severe AS is not present.
There are many other limitations in estimating aortic valve area in patients with aortic stenosis using echocardiography and cardiac catheterization . . . . Accurate measurement of the aortic valve area in patients with aortic stenosis can be difficult in the setting of low cardiac output or concomitant aortic or mitral regurgitations. Concomitant aortic regurgitation or low cardiac output can overestimate the severity of aortic stenosis. Furthermore, because of the dependence of aortic valve area calculation on cardiac output, any under or overestimation of cardiac output will cause inaccurate measurement of valve area. This is particularly important in patients with tricuspid regurgitation. Falsely measured aortic valve area could cause inappropriate aortic valve surgery in patients who do not need it.
Other Visceral Organs
Visceral organs such as the gastrointestinal tract and the urinary tract serve to transport luminal contents (fluids) from one end of the organ to the other end or to an absorption site. The esophagus, for example, transports swallowed material from the pharynx to the stomach. Diseases may affect the transport function of the organs by changing the luminal cross-sectional area, the peristalsis generated by muscle, or by changing the tissue components. For example, strictures in the esophagus and urethra constitute a narrowing of the organ where fibrosis of the wall may occur. Strictures and narrowing can be treated with distension, much like the treatment of plaques in the coronary arteries.
The disclosure of the present application provides for a system for measuring cross-sectional areas and pressure gradients in luminal organs. The disclosure of the present application also provides a method and apparatus for measuring cross-sectional areas and pressure gradients in luminal organs, such as, for example, blood vessels, heart valves, and other visceral hollow organs.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method comprises the steps of introducing a device into a treatment site; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at a first position of the treatment site; measuring a first treatment site conductance at the first position of the treatment site; moving the device to a second position of the treatment site at a first speed; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at the second position of the treatment site; measuring a second treatment site conductance at the second position of the treatment site; and calculating cross-sectional areas of the first position and the second position of the treatment site.
In another embodiment, the treatment site comprises a site selected from the group consisting of a body lumen, a body vessel, a biliary tract, and an esophagus. In yet another embodiment, the treatment site comprises an esophagus, and wherein the step of injecting a known volume of a first solution having a first concentration and a first conductivity comprises the step of administering said first solution to a patient orally. In an additional embodiment, the first solution is NaCl.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method further comprises the step of providing electrical current flow for a period of time to the treatment site through the device. In another embodiment, the first concentration of the first solution does not equal the second concentration of the second solution. In yet another embodiment, the first conductivity of the first solution does not equal the second conductivity of the second solution. In an additional embodiment, the method further comprises the step of calculating a first nodal voltage and a first electrical field based upon the first treatment site conductance value and a first current density. In yet an additional embodiment, the method further comprises the step of applying finite element analysis to the first nodal voltage and the first electrical field, wherein the step of finite element analysis is performed using a finite element software package.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises a catheter. In another embodiment, the catheter comprises an impedance catheter. In yet another embodiment, the catheter comprises a guide catheter.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises a wire. In another embodiment, the wire comprises an impedance wire. In yet another embodiment, the wire comprises a wire selected from the group consisting of a guide wire, a pressure wire, and a flow wire. In an additional embodiment, the wire comprises a flow wire, and wherein the flow wire is operable to measure a velocity of fluid flow.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises an inflatable balloon positioned along a longitudinal axis of the device. In another embodiment, the method further comprises the step of inflating the balloon to breakup materials causing stenosis at the treatment site. In yet another embodiment, the device further comprises a stent located over the balloon, the stent capable of being distended to a desired size and implanted into the treatment site. In an additional embodiment, the method further comprises the steps of distending the stent by inflating the underlying balloon; and releasing and implanting the stent into the treatment site. In yet an additional embodiment, the balloon is inflated using a fluid, and the method further comprises the steps of providing electrical current into the fluid filling the balloon at various degrees of balloon distension; measuring a conductance of the fluid inside the balloon; and calculating a cross-sectional area of the balloon lumen.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method further comprises the steps of selecting an appropriately-sized stent based on a cross-sectional area of the treatment site; and implanting the stent into the treatment site. In another embodiment, the device comprises a pressure transducer. In yet another embodiment, the method further comprising the steps of measuring a first pressure gradient from the pressure transducer near the treatment site; and calculating the cross-sectional area of the treatment site based in part on the first pressure gradient.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the step of injecting a known volume of a first solution having a first concentration and a first conductivity temporarily substantially displaces blood present at the treatment site. In another embodiment, the first solution is heated to an internal body temperature of a body surrounding the treatment site prior to injection. In yet another embodiment, wherein the first solution and the second solution are heated to a common temperature prior to injection. In an additional embodiment, the first volume of the first solution is equal to the second volume of the second solution.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the step of measuring a first treatment site conductance further comprises the step of measuring a first cross-sectional area, and wherein the step of measuring a second treatment site conductance further comprises the step of measuring a second cross-sectional area. In another embodiment, the method further comprises the step of constructing a profile of the treatment site based in part on the measurements of the first cross-sectional area and the second cross-sectional area. In yet another embodiment, the step of moving the device comprises pulling back the device to a second position of the treatment site. In an additional embodiment, the step of moving the device comprises pushing the device forward to a second position of the treatment site.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the calculation of the cross-sectional areas of the first position and the second position of the treatment site is based in part upon the first treatment site conductance, the second treatment site conductance, the first conductivity of the first solution, and the second conductivity of the second solution. In another embodiment, the method further comprises the step of calculating two Coeff ratios based in part upon the first treatment site conductance, the second treatment site conductance, and the cross-sectional areas of the first position and the second position of the treatment site. In yet another embodiment, the step of moving the device to a second position of the treatment site further comprises the steps of obtaining one or more additional conductance measurements between the first position and the second position of the treatment site; and calculating one or more additional cross-sectional areas based upon the one or more additional conductance measurements. In an additional embodiment, the method further comprises the step of determining one or more diameters based in part upon the cross-sectional areas of the first position and the second position of the treatment site and the one or more additional cross-sectional areas based upon the additional conductance measurements.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method further comprises the step of constructing a profile of the treatment site based upon the one or more diameters. In another embodiment, the method further comprises the step of calculating total conductance for a distance between the first position and the second position of the treatment site. In yet another embodiment, the method further comprises the step of constructing a profile of the treatment site based upon the cross-sectional areas. In an additional embodiment, the step of injecting a known volume of a first solution having a first concentration and a first conductivity comprises injecting the first solution local to the first position of the treatment site.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises a stent positioned along a longitudinal axis of the device, the stent capable of being distended to a desired size and implanted into the treatment site. In another embodiment, the method further comprises the steps of positioning the stent at or near the treatment site; distending the stent; and releasing and implanting the stent into the treatment site. In yet another embodiment, the method further comprises the step of introducing a stent at or near the treatment site, the stent having a length, a collapsed diameter, and a distended diameter. In an additional embodiment, a stent having a particular length is selected based upon a length of a stenosis. In yet an additional embodiment, the length of the stenosis is determined based upon a profile created in part based upon the cross-sectional areas of the first position and/or the second position of the treatment site.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, a stent having a particular collapsed diameter is selected based upon the cross-sectional areas of the first position and/or the second position of the treatment site. In another embodiment, a stent having a particular distended diameter is selected based upon the cross-sectional areas of the first position and/or the second position of the treatment site. In yet another embodiment, the first treatment site conductance and the second treatment site conductance are retrieved by a data acquisition and processing system operably connected to the device, and wherein the data acquisition and processing system is operable to calculate cross-sectional areas.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises at least one suction/infusion port in communication with at least one lumen of the device, whereby said injections of solutions occur via the at least one suction/infusion port. In another embodiment, the device further comprises at least one solution delivery source operably coupled to the at least one lumen of the device, whereby the first solution and the second solution may be injected from the at least one solution delivery source through the at least one lumen of the device, through the at least one suction/infusion port, and into the treatment site. In yet another embodiment, the device comprises at least one excitation electrode and at least one detection electrode. In an additional embodiment, the at least one excitation electrode comprises a first excitation impedance lead, and wherein the at least one detection electrode comprises a first detection impedance lead.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the treatment site has a relative longitudinal axis, and wherein the method further comprises the step of constructing a profile along the relative longitudinal axis of the treatment site based in part on the first and second cross-sectional area measurements. In another embodiment, the treatment site has a relative longitudinal axis, and wherein the step of moving the device to a second position of the treatment site further comprises the steps of obtaining one or more additional conductance measurements between the first position and the second position of the treatment site; and calculating one or more additional cross-sectional areas based upon the one or more additional conductance measurements. In another embodiment, the method further comprises the step of constructing a profile along the relative longitudinal axis of the treatment site based in part on the first and second cross-sectional area measurements and the one or more additional cross-sectional areas. In yet another embodiment, the method further comprises the step of comprising the step of determining one or more diameters based in part upon the cross-sectional areas of the first position and the second position of the treatment site and the one or more additional cross-sectional areas based upon the additional conductance measurements. In an additional embodiment, the method further comprises the step of constructing a profile of the treatment site based upon the one or more diameters.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises a sensor for measurement of fluid flow. In another embodiment, the device is dimensioned so that a first solution can be infused therethrough. In yet another embodiment, the data acquisition and processing system is operable to receive conductance data from the device at a first treatment site, and wherein the data acquisition and processing system is further operable to determine the first treatment site conductance based in part from the conductance data.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the device comprises a catheter having a lumen, a proximal end, and a distal end, and wherein the at least one excitation electrode and the at least one detection electrode are positioned at or near the distal end of the catheter. In another embodiment, the at least one excitation electrode and the at least one detection electrode have insulated electrical wire connections that run through the lumen and proximal end of the catheter. In yet another embodiment, the at least one excitation electrode and the at least one detection electrode have electrical wire connections that are embedded within the catheter such that each wire comprising the electrical wire connections are insulated from the other wires.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the catheter comprises a lumen extending therethrough, and further comprising a wire positioned through at least a portion of the lumen of the catheter.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method comprises the steps of introducing a device into a treatment site; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at a first position of the treatment site; measuring a first treatment site conductance at the first position of the treatment site; pulling back the device to a second position of the treatment site at a first speed while injecting a known volume of the second solution, wherein the second position is located proximally relative to the first position; injecting a known volume of a first solution having a first concentration and a first conductivity at the second position of the treatment site; measuring a second treatment site conductance at the second position of the treatment site; and calculating cross-sectional areas of the first position and the second position of the treatment site based in part upon the first treatment site conductance, the second treatment site conductance, the first conductivity of the first solution, and the second conductivity of the second solution. In another embodiment, the method further comprises the step of constructing a profile of the treatment site based in part on the measurements of the first cross-sectional area and the second cross-sectional area. In yet another embodiment, the device comprises an inflatable balloon along a longitudinal axis of the device.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method further comprises the step of inflating the balloon to breakup any materials causing stenosis at the treatment site. In another embodiment, the device further comprises a stent located over the balloon, the stent capable of being distended to a desired lumen size and implanted into the treatment site. In yet another embodiment, the method further comprises the steps of distending the stent by inflating the underlying balloon; and releasing and implanting the stent into the treatment site. In an additional embodiment, the balloon is inflated using a fluid, and the method further comprises the steps of providing electrical current into the fluid filling the balloon at various degrees of balloon distension; measuring a conductance of the fluid inside the balloon; and calculating a cross-sectional area of the balloon lumen.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method further comprises the steps of selecting an appropriately-sized stent based on a cross-sectional area of the treatment site; and implanting the stent into the treatment site. In another embodiment, the step of pulling back the device to a second position of the treatment site further comprises the step of obtaining one or more additional conductance measurements between the first position and the second position of the treatment site and the step of calculating one or more additional cross-sectional areas based upon the one or more additional conductance measurements. In yet another embodiment, the method further comprises the step of constructing a profile of the treatment site based in part upon the cross-sectional area of the first position and the second position of the treatment site and the one or more additional cross-sectional areas based upon the additional conductance measurements.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method comprises the steps of calculating a total conductance based upon individual conductance values taken at a proximal end and a distal end of a segment; calculating two Coeff ratios based upon the total conductance and the cross-sectional areas of the proximal and the distal end of the segment; linearly interpolating along a length of pull back of a device for the Coeff so that the proximal and the distal end of the segment have the same Coeffs as calculated herein; calculating a total conductance for the length of the pull back; multiplying the total conductance for the length of the pull back by its respective Coeff for at least one point calculated during pull back to obtain a cross-sectional area for the at least one point calculated during pull back; and determining the diameter for the at least one point calculated during pull back from the cross-sectional area for the at least one point calculated during pull back.
In another embodiment, the step of calculating two Coeff ratios is performed by dividing the two cross-sectional areas by the total conductance. In yet another embodiment, the step of determining the diameter for the at least one point is determined by multiplying the cross-sectional area of the at least one point by four, dividing the resulting product by pi, and taking the square root of the resulting quotient.
According to at least one embodiment of a method for measuring a cross-sectional area of a targeted treatment site, the method comprises the steps of introducing a device into a treatment site; injecting a known volume of a first solution having a first concentration and a first conductivity at a first position of the treatment site; measuring a first conductance at the first position of the treatment site; injecting a known volume of a second solution having a second concentration and a second conductivity at a first position of the treatment site; measuring a second conductance at the first position of the treatment site; moving the device to a second position of the treatment site at a first speed; injecting a known volume of a first solution having a first concentration and a first conductivity at the second position of the treatment site; measuring a third conductance at the second position of the treatment site; injecting a known volume of a second solution having a second concentration and a second conductivity at the second position of the treatment site; measuring a fourth conductance at the second position of the treatment site; and calculating cross-sectional areas of the first position and the second position of the treatment site based in part from the first conductance, the second conductance, the third conductance, and the fourth conductance.
According to at least one embodiment of a method for constructing a profile of a targeted treatment site, the method comprises the steps of introducing a device into a treatment site; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at a first position of the treatment site; measuring a first treatment site conductance at the first position of the treatment site; moving the device to a second position of the treatment site at a first speed; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at the second position of the treatment site; measuring a second treatment site conductance at the second position of the treatment site; calculating cross-sectional areas of the first position and the second position of the treatment site; and constructing a profile of the treatment site based upon the cross-sectional areas of the first position and the second position of the treatment site.
In another embodiment, the step of moving the device to a second position of the treatment site further comprises the steps of obtaining one or more additional conductance measurements between the first position and the second position of the treatment site; and calculating one or more additional cross-sectional areas based upon the one or more additional conductance measurements. In yet another embodiment, the method further comprises the step of constructing a profile of the treatment site based upon the cross-sectional areas of the first position and the second position of the treatment site and the one or more additional cross-sectional areas.
According to at least one embodiment of a method for implanting a stent to a targeted treatment site, the method comprises the steps of introducing a device into a treatment site; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at a first position of the treatment site; measuring a first treatment site conductance at the first position of the treatment site; moving the device to a second position of the treatment site at a first speed; injecting a known volume of a first solution having a first concentration and a first conductivity and injecting a known volume of a second solution having a second concentration and a second conductivity at the second position of the treatment site; measuring a second treatment site conductance at the second position of the treatment site; calculating cross-sectional areas of the first position and the second position of the treatment site; selecting an appropriately-sized stent based on a cross-sectional area of the treatment site; and implanting the stent into the treatment site.
The disclosure of the present application provides devices, systems, and methods to obtain accurate measures of the luminal cross-sectional area of organ stenosis within acceptable limits to enable accurate and scientific stent sizing and placement in order to improve clinical outcomes by avoiding under or over deployment and under or over sizing of a stent which can cause acute closure or in-stent re-stenosis. For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to the embodiments illustrated in the drawings, and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the present disclosure is thereby intended.
In one embodiment, an angioplasty or stent balloon includes impedance electrodes supported by the catheter in front of the balloon. These electrodes enable the immediate measurement of the cross-sectional area of the vessel during the balloon advancement. This provides a direct measurement of non-stenosed area and allows the selection of the appropriate stent size. In one approach, error due to the loss of current in the wall of the organ and surrounding tissue is corrected by injection of two solutions of NaCl or other solutions with known conductivities. In another embodiment impedance electrodes are located in the center of the balloon in order to deploy the stent to the desired cross-sectional area. These embodiments and procedures substantially improve the accuracy of stenting and the outcome and reduce the cost.
Other embodiments make diagnosis of valve stenosis more accurate and more scientific by providing a direct accurate measurement of cross-sectional area of the valve annulus, independent of the flow conditions through the valve. Other embodiments improve evaluation of cross-sectional area and flow in organs like the gastrointestinal tract and the urinary tract.
Embodiments of the disclosure of the present application overcome the problems associated with determination of the size (cross-sectional area) of luminal organs, such as, for example, in the coronary arteries, carotid, femoral, renal and iliac arteries, aorta, gastrointestinal tract, urethra and ureter. Embodiments also provide methods for registration of acute changes in wall conductance, such as, for example, due to edema or acute damage to the tissue, and for detection of muscle spasms/contractions.
As described below, in one preferred embodiment, there is provided an angioplasty catheter with impedance electrodes near the distal end 19 of the catheter (i.e., in front of the balloon) for immediate measurement of the cross-sectional area of a vessel lumen during balloon advancement. This catheter includes electrodes for accurate detection of organ luminal cross-sectional area and ports for pressure gradient measurements. Hence, it is not necessary to change catheters such as with the current use of intravascular ultrasound. In one preferred embodiment, the catheter provides direct measurement of the non-stenosed area, thereby allowing the selection of an appropriately sized stent. In another embodiment, additional impedance electrodes may be incorporated in the center of the balloon on the catheter in order to deploy the stent to the desired cross-sectional area. The procedures described herein substantially improve the accuracy of stenting and improve the cost and outcome as well.
In another embodiment, the impedance electrodes are embedded within a catheter to measure the valve area directly and independent of cardiac output or pressure drop and therefore minimize errors in the measurement of valve area. Hence, measurements of area are direct and not based on calculations with underlying assumptions. In another embodiment, pressure sensors can be mounted proximal and distal to the impedance electrodes to provide simultaneous pressure gradient recording.
Catheter
Exemplary impedance or conductance catheters for use within the disclosure of the present application are illustrated in
In one approach, dimensions of a catheter to be used for any given application depend on the optimization of the potential field using finite element analysis described below. For small organs, or in pediatric patients the diameter of the catheter may be as small as 0.3 mm. In large organs the diameter may be significantly larger depending on the results of the optimization based on finite element analysis. The balloon size will typically be sized according to the preferred dimension of the organ after the distension. The balloon may be made of materials, such as, for example, polyethylene, latex, polyestherurethane, or combinations thereof. The thickness of the balloon will typically be on the order of a few microns. The catheter will typically be made of PVC or polyethylene, though other materials may equally well be used. The excitation and detection electrodes typically surround the catheter as ring electrodes but they may also be point electrodes or have other suitable configurations. These electrodes may be made of any conductive material, preferably of platinum iridium or a carbon-coasted surface to avoid fibrin deposits. In a preferred embodiment, the detection electrodes are spaced with 0.5-1 mm between them and with a distance between 4-7 mm to the excitation electrodes on small catheters. The dimensions of the catheter selected for a treatment depend on the size of the vessel and are preferably determined in part on the results of finite element analysis, described below. On large catheters, for use in larger vessels and other visceral hollow organs, the electrode distances may be larger.
Referring to
The catheter 20 may also advantageously include several miniature pressure transducers (not shown) carried by the catheter or pressure ports for determining the pressure gradient proximal at the site where the cross-sectional area is measured. The pressure is preferably measured inside the balloon and proximal, distal to and at the location of the cross-sectional area measurement, and locations proximal and distal thereto, thereby enabling the measurement of pressure recordings at the site of stenosis and also the measurement of pressure-difference along or near the stenosis. In one embodiment, shown in
In one embodiment, a fluid-filled silastic pressure-monitoring catheter is connected to a pressure transducer. Luminal pressure can be monitored by a low compliance external pressure transducer coupled to the infusion channel of the catheter. Pressure transducer calibration was carried out by applying 0 and 100 mmHg of pressure by means of a hydrostatic column.
In one embodiment, shown in
In one embodiment, the cross-sectional area may be measured using a two-electrode system. In another embodiment, illustrated in
The tip of the catheter can be straight, curved or with an angle to facilitate insertion into the coronary arteries or other lumens, such as, for example, the biliary tract. The distance between the balloon and the electrodes is usually small, in the 0.5-2 cm range but can be closer or further away, depending on the particular application or treatment involved.
In another embodiment, shown in
With reference to the embodiment shown in
With reference to the embodiments shown in
In another embodiment (not illustrated), the catheter may contain an extra channel for insertion of a guide wire to stiffen the flexible catheter during the insertion or data recording. In yet another embodiment (not illustrated), the catheter may include a sensor for measurement of the flow of fluid in the body organ.
System for Determining Cross-Sectional Area and Pressure Gradient
The operation of the impedance catheter 20 is as follows: With reference to the embodiment shown in
where Gp(z,t) is the effective conductance of the structure outside the bodily fluid (organ wall and surrounding tissue) at a given position, z, along the long axis of the organ at a given time, t, and Cb is the electrical conductivity of the bodily fluid which for blood generally depends on the temperature, hematocrit and orientation and deformation of blood cells, and L is the distance between the detection electrodes. Equation [1a] can be rearranged to solve for cross sectional area CSA(t), with a correction factor, a, if the electric field is non-homogeneous, as
where a would be equal to 1 if the field were completely homogeneous. The parallel conductance, Gp, is an offset error that results from current leakage. Gp would equal 0 if all of the current were confined to the blood and hence would correspond to the cylindrical model given by Equation [10]. In one approach, finite element analysis is used to properly design the spacing between detection and excitation electrodes relative to the dimensions of the vessel to provide a nearly homogenous field such that a can be considered equal to 1. Our simulations show that a homogenous or substantially homogenous field is provided by (1) the placement of detection electrodes substantially equidistant from the excitation electrodes and (2) maintaining the distance between the detection and excitation electrodes substantially comparable to the vessel diameter. In one approach, a homogeneous field is achieved by taking steps (1) and/or (2) described above so that a is equals 1 in the foregoing analysis.
At any given position, z, along the long axis of organ and at any given time, t, in the cardiac cycle, Gp is a constant. Hence, two injections of different concentrations and/or conductivities of NaCl solution give rise to two equations:
C1•CSA(z,t)−L•Gp(z,t)=L•G1(z,t) [2]
and
C2•CSA(z,t)+L•Gp(z,t)=L•G2(z,t) [3]
which can be solved simultaneously for CSA and Gp as
where subscript “1” and subscript “2” designate any two injections of different NaCl concentrations and/or conductivities. For each injection k, Ck gives rise to Gk which is measured as the ratio of the root mean square of the current divided by the root mean square of the voltage. The Ck is typically determined through in vitro calibration for the various NaCl concentrations and/or conductivities. The concentration of NaCl used is typically on the order of 0.45 to 1.8%. The volume of NaCl solution is typically about 5 ml, but sufficient to displace the entire local vascular blood volume momentarily. The values of CSA(t) and Gp(t) can be determined at end-diastole or end-systole (i.e., the minimum and maximum values) or the mean thereof.
Once the CSA and Gp of the vessel are determined according to the above embodiment, rearrangement of Equation [1a] allows the calculation of the electrical conductivity of blood in the presence of blood flow as
In this way, Equation [1b] can be used to calculate the CSA continuously (temporal variation as for example through the cardiac cycle) in the presence of blood.
In one approach, a pull or push through is used to reconstruct the vessel along its length. During a long injection (e.g., 10-15 s), the catheter can be pulled back or pushed forward at constant velocity, U. Equation [1b] can be expressed as
where the axial position, z, is the product of catheter velocity, U, and time, t; i.e., z=U·t.
For the two injections, denoted by subscript “1” and subscript “2”, respectively, different time points T1, T2, etc., may be considered such that equation [7] can be written as
and so on. Each set of equations [8a], [8b] and [9a], [9b], etc. can be solved for CSA1, Gp1 and CSA2, Gp2, respectively. Hence, the CSA at various time intervals may be measured and hence of different positions along the vessel to reconstruct the length of the vessel. In one embodiment, the data on the CSA and parallel conductance as a function of longitudinal position along the vessel can be exported from an electronic spreadsheet, such as, for example, an Excel file, to AutoCAD where the software uses the coordinates to render a profile on the monitor.
For example, in one exemplary approach, the pull back reconstruction was made during a long injection where the catheter was pulled back at constant rate by hand. The catheter was marked along its length such that the pull back was made at 2 mm/sec. Hence, during a 10 second injection, the catheter was pulled back about 2 cm. The data was continuously measured and analyzed at every two second interval; i.e., at every 4 mm. Hence, six different measurements of CSA and Gp were made which were used to reconstruct the CSA and Gp along the length of the 2 cm segment, namely at 0 mm, 4 mm, 8 mm, 12 mm, 16 mm, and 20 mm.
Operation of the impedance catheter 39: With reference to the embodiment shown in
where G is conductance expressed as the ratio of current to voltage, I/ΔV. Equation [10] is identical to Equation [1b] if the parallel conductance through the vessel wall is neglected and surrounding tissue because the balloon material acts as an insulator. This is the cylindrical model on which the conductance method is used.
As described below with reference to
Pressure conduits for perfusion manometry connect the pressure ports 90, 91 to transducers included in the data acquisition system 100. As shown in
With reference to
In one preferred embodiment, the system is pre-calibrated and the probe is available in a package. Here, the package also preferably contains sterile syringes with the fluids to be injected. The syringes are attached to the machine and after heating of the fluid by the machine and placement of the probe in the organ of interest, the user presses a button that initiates the injection with subsequent computation of the desired parameters. The cross-sectional area, CSA, and parallel conductance, Gp, and other relevant measures such as distensibility, tension, etc. will typically appear on the display panel in the PC module 160. Here, the user can then remove the stenosis by distension or by placement of a stent.
If more than one CSA is measured, the system can contain a multiplexer unit or a switch between CSA channels. In one embodiment, each CSA measurement will be through separate amplifier units. The same may account for the pressure channels.
In one embodiment, the impedance and pressure data are analog signals which are converted by analog-to-digital converters 150 and transmitted to a computer 160 for on-line display, on-line analysis and storage. In another embodiment, all data handling is done on an entirely analog basis. The analysis advantageously includes software programs for reducing the error due to conductance of current in the organ wall and surrounding tissue and for displaying profile of the CSA distribution along the length of the vessel along with the pressure gradient. In one embodiment of the software, a finite element approach or a finite difference approach is used to derive the CSA of the organ stenosis taking parameters such as conductivities of the fluid in the organ and of the organ wall and surrounding tissue into consideration. In another embodiment, simpler circuits are used; e.g., based on making two or more injections of different NaCl solutions to vary the resistivity of fluid in the vessel and solving the two simultaneous Equations [2] and [3] for the CSA and parallel conductance (Equations [4] and [5], respectively). In another embodiment, the software contains the code for reducing the error in luminal CSA measurement by analyzing signals during interventions such as infusion of a fluid into the organ or by changing the amplitude or frequency of the current from the constant current amplifier. The software chosen for a particular application, preferably allows computation of the CSA with only a small error instantly or within acceptable time during the medical procedure.
In one approach, the wall thickness is determined from the parallel conductance for those organs that are surrounded by air or non-conducting tissue. In such cases, the parallel conductance is equal to
where CSAw is the wall area of the organ and G is the electrical conductivity through the wall. This equation can be solved for the wall CSAw as
For a cylindrical organ, the wall thickness, h, can be expressed as
where D is the diameter of the vessel which can be determined from the circular CSA (D=[4CSA/π]1/2).
When the CSA, pressure, wall thickness, and flow data are determined according to the embodiments outlined above, it is possible to compute the compliance (e.g., ΔCSA/ΔP), tension (e.g., P·r, where P and r are the intraluminal pressure and radius of a cylindrical organ), stress (e.g., P·r/h where h is the wall thickness of the cylindrical organ), strain (e.g., (C−Cd)/Cd where C is the inner circumference and Cd is the circumference in diastole) and wall shear stress (e.g., 4 μQ/r3 where μ Q and r are the fluid viscosity, flow rate and radius of the cylindrical organ, respectively, for a fully developed flow). These quantities can be used in assessing the mechanical characteristics of the system in health and disease.
Exemplary Method
In one approach, luminal cross-sectional area is measured by introducing a catheter from an exteriorly accessible opening (e.g., mouth, nose, or anus for GI applications; or e.g., mouth or nose for airway applications) into the hollow system or targeted luminal organ. For cardiovascular applications, the catheter can be inserted into the organs in various ways; e.g., similar to conventional angioplasty. In one embodiment, an 18 gauge needle is inserted into the femoral artery followed by an introducer. A guide wire is then inserted into the introducer and advanced into the lumen of the femoral artery. A 4 or 5 Fr conductance catheter is then inserted into the femoral artery via wire and the wire is subsequently retracted. The catheter tip containing the conductance electrodes can then be advanced to the region of interest by use of x-ray (i.e., fluoroscopy). In another approach, this methodology is used on small to medium size vessels (e.g., femoral, coronary, carotid, iliac arteries, etc.).
In one approach, a minimum of two injections (with different concentrations and/or conductivities of NaCl) are required to solve for the two unknowns, CSA and Gp. In another approach, three injections will yield three set of values for CSA and Gp (although not necessarily linearly independent), while four injections would yield six set of values. In one approach, at least two solutions (e.g., 0.5% and 1.5% NaCl solutions) are injected in the targeted luminal organ or vessel. Our studies indicate that an infusion rate of approximately 1 ml/s for a five second interval is sufficient to displace the blood volume and results in a local pressure increase of less than 10 mmHg in the coronary artery. This pressure change depends on the injection rate which should be comparable to the organ flow rate.
In one preferred approach, involving the application of Equations [4] and [5], the vessel is under identical or very similar conditions during the two injections. Hence, variables, such as, for example, the infusion rate, bolus temperature, etc., are similar for the two injections. Typically, a short time interval is to be allowed (1-2 minute period) between the two injections to permit the vessel to return to homeostatic state. This can be determined from the baseline conductance as shown in
In one approach, the NaCl solution is heated to body temperature prior to injection since the conductivity of current is temperature dependent. In another approach, the injected bolus is at room temperature, but a temperature correction is made since the conductivity is related to temperature in a linear fashion.
In one approach, a sheath is inserted either through the femoral or carotid artery in the direction of flow. To access the lower anterior descending (LAD) artery, the sheath is inserted through the ascending aorta. For the carotid artery, where the diameter is typically on the order of 5-5.5 mm, a catheter having a diameter of 1.9 mm can be used, as determined from finite element analysis, discussed further below. For the femoral and coronary arteries, where the diameter is typically in the range from 3.5-4 mm, so a catheter of about 0.8 mm diameter would be appropriate. The catheter can be inserted into the femoral, carotid or LAD artery through a sheath appropriate for the particular treatment. Measurements for all three vessels can be made similarly.
Described here are the protocol and results for one exemplary approach that is generally applicable to most arterial vessels. The conductance catheter was inserted through the sheath for a particular vessel of interest. A baseline reading of voltage was continuously recorded. Two containers containing 0.5% and 1.5% NaCl were placed in temperature bath and maintained at 37°. A 5-10 ml injection of 1.5% NaCl was made over a 5 second interval. The detection voltage was continuously recorded over a 10 second interval during the 5 second injection. Several minutes later, a similar volume of 1.5% NaCl solution was injected at a similar rate. The data was again recorded. Matlab was used to analyze the data including filtering with high pass and with low cut off frequency (1200 Hz). The data was displayed using Matlab and the mean of the voltage signal during the passage of each respective solution was recorded. The corresponding currents were also measured to yield the conductance, G=I/V. The conductivity of each solution was calibrated with six different tubes of known CSA at body temperature. A model using Equation [10] was fitted to the data to calculate conductivity C. The analysis was carried out in SPSS using the non-linear regression fit. Given C and G for each of the two injections, an excel sheet file was formatted to calculate the CSA and Gp as per Equations [4] and [5], respectively. These measurements were repeated several times to determine the reproducibility of the technique. The reproducibility of the data was within 5%. Ultrasound (US) was used to measure the diameter of the vessel simultaneous with our conductance measurements. The detection electrodes were visualized with US and the diameter measurements was made at the center of the detection electrodes. The maximum differences between the conductance and US measurements were within 10%.
With reference to
The voltage signals are ideal since the difference between the baseline and the injected solution is apparent and systematic. Furthermore, the pulsation of vessel diameter can be seen in the 0.5% and 1.5% NaCl injections (
The NaCl solution can be injected by hand or by using a mechanical injector to momentarily displace the entire volume of blood or bodily fluid in the vessel segment of interest. The pressure generated by the injection will not only displace the blood in the antegrade direction (in the direction of blood flow) but also in the retrograde direction (momentarily push the blood backwards). In other visceral organs which may be normally collapsed, the NaCl solution will not displace blood as in the vessels but will merely open the organs and create a flow of the fluid. In one approach, after injection of a first solution into the treatment or measurement site, sensors monitor and confirm baseline of conductance prior to injection of a second solution into the treatment site.
The injections described above are preferably repeated at least once to reduce errors associated with the administration of the injections, such as, for example, where the injection does not completely displace the blood or where there is significant mixing with blood. It will be understood that any bifurcation(s) (with branching angle near 90 degrees) near the targeted luminal organ can cause an overestimation of the calculated CSA. Hence, generally the catheter should be slightly retracted or advanced and the measurement repeated. An additional application with multiple detection electrodes or a pull back or push forward during injection will accomplish the same goal. Here, an array of detection electrodes can be used to minimize or eliminate errors that would result from bifurcations or branching in the measurement or treatment site.
In one approach, error due to the eccentric position of the electrode or other imaging device can be reduced by inflation of a balloon on the catheter. The inflation of balloon during measurement will place the electrodes or other imaging device in the center of the vessel away from the wall. In the case of impedance electrodes, the inflation of balloon can be synchronized with the injection of bolus where the balloon inflation would immediately precede the bolus injection. Our results, however, show that the error due to catheter eccentricity is small.
The CSA predicted by Equation [4] corresponds to the area of the vessel or organ external to the catheter (i.e., CSA of vessel minus CSA of catheter). If the conductivity of the NaCl solutions is determined by calibration from Equation [10] with various tubes of known CSA, then the calibration accounts for the dimension of the catheter and the calculated CSA corresponds to that of the total vessel lumen as desired. In one embodiment, the calibration of the CSA measurement system will be performed at 37° C. by applying 100 mmHg in a solid polyphenolenoxide block with holes of known CSA ranging from 7.065 mm2 (3 mm in diameter) to 1017 mm2 (36 mm in diameter). If the conductivity of the solutions is obtained from a conductivity meter independent of the catheter, however, then the CSA of the catheter is generally added to the CSA computed from Equation [4] to give the desired total CSA of the vessel.
The signals are generally non-stationary, nonlinear and stochastic. To deal with non-stationary stochastic functions, one can use a number of methods, such as the Spectrogram, the Wavelet's analysis, the Wigner-Ville distribution, the Evolutionary Spectrum, Modal analysis, or preferably the intrinsic model function (IMF) method. The mean or peak-to-peak values can be systematically determined by the aforementioned signal analysis and used in Equation [4] to compute the CSA.
Exemplary Four-Injection Approach
In at least one method of the disclosure of the present application, a four-injection approach is provided. As previously disclosed herein, two injections provide the cross-sectional area, CSA, and parallel conductance, Gp, at a particular point.
In at least one approach, four injections are provided to determine parallel conductance at multiple points. In an exemplary study, four injections may be performed to determine a segment of 2-3 cm long or longer. In this study, two injections may be performed at the distal end of the segment, and two injections may be performed at the proximal end of the segment. The two injections may deliver, for example, a volume of 1.5% NaCl and a volume of 0.5% NaCl, at each end of the segment, noting that any number of solutions, volumes, and concentrations thereof suitable for such a study, or for the other studies contemplated by the disclosure of the present application, could be utilized. For example, solutions having different salinities can be introduced in various physiological saline solutions (PSS) or in a Kreb solution containing other ions such as potassium, sodium, etc. In this exemplary study, the first two injections (1.5% NaCl and 0.5% NaCl) may be made at the distal point of the segment, and the catheter system would then be pulled back to the proximal point of the segment, whereby two more injections (1.5% NaCl and 0.5% NaCl) may be made, with conductance values taken at the distal end and the proximal end of the segment used to determine the entire profile of the segment.
As referenced herein with respect to Equation [1a], conductance may be calculated taking into account cross-sectional area, electrical conductivity of a fluid, and effective conductance of a structure. When performing a study as described above, the two end points (proximal and distal ends of a segment) are clearly exact, and an intermediate profile between those two points can be derived based upon the analysis provided herein. Since the cross-sectional area, CSA, and parallel conductance at a point, Gp, are known at each of the two ends of a segment, the corresponding blood conductivity may be calculated:
where GTotal is the total conductance (current divided by voltage), CSA is the cross-sectional area, Cb is the blood conductivity, L is the detection electrode spacing on the catheter, and Gp is the parallel conductance at a point. The mean of the two values may then be calculated based upon the foregoing.
A procedure as described above may be accomplished, for example, by performing the following steps:
A mathematical explanation of the concept referenced in the procedure above is as follows. First, the equation governing the physics of electrical conductance has the following form:
where GTotal is the total conductance, I is the current, V is the voltage, CSA is the cross-sectional area, σ is the conductivity of the fluid, L is the detection electrode spacing on the catheter, and Gp is the parallel conductance at a point.
Experimentation as shown that parallel conductance (Gp) is linearly related to cross-sectional area, with a negative slope. For example, a larger CSA has a smaller Gp. As such, Gp can be replaced with a linear function of CSA as follows:
where GTotal is the total conductance, I is the current, V is the voltage, CSA is the cross-sectional area, σ is the conductivity of the fluid, L is the detection electrode spacing on the catheter, m is the slops, and b is the intercept as can be determined for a linear least square fit. This may be rearranged as follows:
It is shown that total conductance (GTotal) is clearly linearly related to cross-sectional area (CSA). If the coefficient b is ignored (wherein b should be equal to zero if CSA is equal to zero), then we have the following:
The Coeff value at both ends of a segment can be found where the two injections are made, and those values may then be used to linearly interpolate across the profile. Once a Coeff value for every point in the pull back is determined, those Coeff values are multiplied by their respective GTotal values to determine the CSA values along the profile, namely:
CSA=Coeff*GTotal [18]
and
to determine a diameter.
Exemplary Three-Injection Approach
In at least one method of the disclosure of the present application, a three-injection approach to determine a profile as outlined above with respect to the four-injection approach is also provided. In at least one approach, three injections are provided, with two injections at the distal end of a segment, simultaneous withdrawal of one of the injection sources, and one injection at the proximal end of the segment.
In an exemplary study, the first two injections at the distal end may deliver, for example, a volume of 1.5% NaCl and a volume of 0.5% NaCl, noting that any number of solutions, volumes, and concentrations thereof suitable for such a study could be utilized. In this exemplary study, the first two injections (1.5% NaCl and 0.5% NaCl) may be made at the distal point of the segment, wherein the catheter system is simultaneously withdrawn with the injection of the 0.5% NaCl so that the 0.5% NaCl may also be used for the proximal end. These injections would then be followed by a 1.5% NaCl injection at the proximal end of the segment.
Advantages to this particular approach over the four-injection approach are that (1) the conductivity would be simplified as that of 0.5% rather than blood, and (2) there are only three injections required instead of four. However, the three-injection method also requires that a physician using a catheter system to perform such a procedure would be required to inject and pull back simultaneously. A physician comfortable with simultaneous injection and pull back may prefer the three-injection approach, while a physician not comfortable with simultaneous injection and pull back may prefer the four-injection approach. Either approach is possible using the algorithm provided herein.
Ex-vivo and In-Vivo Validation of Algorithm
Studies were performed ex-vivo in in-vivo to validate the algorithm provided herein. The former was validated in a carotid artery with an artificial stenosis to compare the algorithm disclosed herein versus cast measurements for both for the two-injection method at several discrete points and the reconstructed profile. The latter validation was done in vivo in a coronary artery (LAD) where a comparison between LR (LumenRecon) and IVUS (intravascular) was made.
Ex-vivo Validation of Algorithm
To validate the algorithm ex-vivo, a segment of a swine carotid artery was removed and mounted on a bench stand as shown in
The LumenRecon system was calibrated using the 0.45% and 1.5% saline concentrations. A two-injection method according to the present disclosure was used to make single diameter measurements at the six locations along the length of the vessel. “Pull back” measurements were also made along the length of the vessel to create a continuous profile of the vessel diameter.
After the LumenRecon measurements were taken, a cast mold of the vessel was created. The diameter of the cast mold of the vessel was determined using microscopy. The cast measurements were taken at the six locations marked by the black indicator and at intermediate locations along the vessel.
The diameters from the LumenRecon two injection method and the pull back measurements were plotted against the cast measurements, respectively.
In Vivo Validation
The LumenRecon system was used to make measurements in the left anterior descending (LAD) coronary artery in an anesthesized swine. A two-injection method of the present disclosure was used to construct a profile which was compared to IVUS at four different locations along the profile.
Referring to the embodiment shown in
For valve area determination, it is not generally feasible to displace the entire volume of the heart. Hence, the conductivity of blood is changed by injection of hypertonic NaCl solution into the pulmonary artery which will transiently change the conductivity of blood. If the measured total conductance is plotted versus blood conductivity on a graph, the extrapolated conductance at zero conductivity corresponds to the parallel conductance. In order to ensure that the two inner electrodes are positioned in the plane of the valve annulus (2-3 mm), in one preferred embodiment, the two pressure sensors 36 are advantageously placed immediately proximal and distal to the detection electrodes (1-2 mm above and below, respectively) or several sets of detection electrodes (see, e.g.,
In one approach, for the esophagus or the urethra, the procedures can conveniently be done by swallowing fluids of known conductances into the esophagus and infusion of fluids of known conductances into the urinary bladder followed by voiding the volume. In another approach, fluids can be swallowed or urine voided followed by measurement of the fluid conductances from samples of the fluid. The latter method can be applied to the ureter where a catheter can be advanced up into the ureter and fluids can either be injected from a proximal port on the probe (will also be applicable in the intestines) or urine production can be increased and samples taken distal in the ureter during passage of the bolus or from the urinary bladder.
In one approach, concomitant with measuring the cross-sectional area and or pressure gradient at the treatment or measurement site, a mechanical stimulus is introduced by way of inflating the balloon or by releasing a stent from the catheter, thereby facilitating flow through the stenosed part of the organ. In another approach, concomitant with measuring the cross-sectional area and or pressure gradient at the treatment site, one or more pharmaceutical substances for diagnosis or treatment of stenosis is injected into the treatment site. For example, in one approach, the injected substance can be smooth muscle agonist or antagonist. In yet another approach, concomitant with measuring the cross-sectional area and or pressure gradient at the treatment site, an inflating fluid is released into the treatment site for release of any stenosis or materials causing stenosis in the organ or treatment site.
Again, it will be noted that the methods, systems, and devices described herein can be applied to any body lumen or treatment site. For example, the methods, systems, and devices described herein can be applied to any one of the following exemplary bodily hollow systems: the cardiovascular system including the heart; the digestive system; the respiratory system; the reproductive system; and the urogential tract.
Finite Element Analysis: In one preferred approach, finite element analysis (FEA) is used to verify the validity of Equations [4] and [5]. There are two major considerations for the model definition: geometry and electrical properties. The general equation governing the electric scalar potential distribution, V, is given by Poisson's equation as:
∇•(C∇V)−−I [13]
where C, I, and ∇ are the conductivity, the driving current density, and the del operator, respectively. Femlab or any standard finite element packages can be used to compute the nodal voltages using equation [13]. Once V has been determined, the electric field can be obtained from as E=−∇V.
The FEA allows the determination of the nature of the field and its alteration in response to different electrode distances, distances between driving electrodes, wall thicknesses and wall conductivities. The percentage of total current in the lumen of the vessel, % I, can be used as an index of both leakage and field homogeneity. Hence, the various geometric and electrical material properties can be varied to obtain the optimum design; i.e., minimize the non-homogeneity of the field. Furthermore, the experimental procedure was simulated by injection of the two solutions of NaCl to verify the accuracy of Equation [4]. Finally, an assessment of the effect of presence of electrodes and catheter in the lumen of vessel may be performed. The error terms representing the changes in measured conductance due to the attraction of the field to the electrodes and the repulsion of the field from the resistive catheter body were quantified.
Poisson's equation for the potential field was solved, taking into account the magnitude of the applied current, the location of the current driving and detection electrodes, and the conductivities and geometrical shapes in the model including the vessel wall and surrounding tissue. This analysis suggest that the following conditions are optimal for the cylindrical model: (1) the placement of detection electrodes equidistant from the excitation electrodes; (2) the distance between the current driving electrodes should be much greater than the distance between the voltage sensing electrodes; and (3) the distance between the detection and excitation electrodes is comparable to the vessel diameter or the diameter of the vessel is small relative to the distance between the driving electrodes. If these conditions are satisfied, the equipotential contours more closely resemble straight lines perpendicular to the axis of the catheter and the voltage drop measured at the wall will be nearly identical to that at the center. Since the curvature of the equipotential contours is inversely related to the homogeneity of the electric field, it is possible to optimize the design to minimize the curvature of the field lines. Consequently, in one preferred approach, one or more of conditions (1)-(3) described above are met to increase the accuracy of the cylindrical model.
Theoretically, it is impossible to ensure a completely homogeneous field given the current leakage through the vessel wall into the surrounding tissue. Research leading to the disclosure of the present application identified that the isopotential line is not constant as one moves out radially along the vessel as stipulated by the cylindrical model. In one embodiment, a catheter with a radius of 0.55 mm is considered whose detected voltage is shown in
In an exemplary embodiment, different diameter catheters are prepackaged and labeled for optimal use in certain size vessel. For example, for vessel dimension in the range of 4-5 mm, 5-7 mm or 7-10 mm, analysis in accordance with the disclosure of the present application shows that the optimum diameter catheters will be in the range of 0.9-1.4, 1.4-2.0 or 2.0-4.6 mm, respectively. A clinician can select the appropriate diameter catheter based on the estimated vessel diameter of interest. This decision will be made prior to the procedure and will serve to minimize the error in the determination of lumen CSA.
It can be appreciated that any number of devices may be used in accordance within the scope of the present disclosure, including, but not limited to, any number of catheters and/or wires. In exemplary embodiments, catheters, including, but not limited to, impedance and/or guide catheters, and wires, including, but not limited to, impedance wires, guide wires, pressure wires, and flow wires, may be used as appropriate as devices, systems, and/or portions of systems of the present disclosure, and may be used as appropriate to perform one or more methods, or steps thereof, of the present disclosure.
While various embodiments of devices, systems, and methods for measuring cross-sectional areas and related calculations, including the generation of profiles of luminal organs using impedance, have been described in considerable detail herein, the embodiments are merely offered by way of non-limiting examples of the disclosure described herein. It will therefore be understood that various changes and modifications may be made, and equivalents may be substituted for elements thereof, without departing from the scope of the disclosure. Indeed, this disclosure is not intended to be exhaustive or to limit the scope of the disclosure.
Further, in describing representative embodiments, the disclosure may have presented a method and/or process as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. Other sequences of steps may be possible. Therefore, the particular order of the steps disclosed herein should not be construed as limitations of the present disclosure. In addition, disclosure directed to a method and/or process should not be limited to the performance of their steps in the order written. Such sequences may be varied and still remain within the scope of the present disclosure.
The present application is related to, claims the priority benefit of, and is a continuation application of U.S. patent application Ser. No. 14/010,139, filed Aug. 26, 2013 and issued as U.S. Pat. No. 9,445,743 on Sep. 20, 2016, which is a continuation application of, U.S. patent application Ser. No. 13/324,222, filed Dec. 13, 2011 and issued as U.S. Pat. No. 9,066,708 on Jun. 30, 2015, which is related to, claims the priority benefit of, and is a continuation application of, U.S. patent application Ser. No. 12/098,242, filed on Apr. 4, 2008 and issued as U.S. Pat. No. 8,078,274 on Dec. 13, 2011, which is related to, claims the priority benefit of, and is a continuation-in-part application of, U.S. patent application Ser. No. 11/891,981, filed Aug. 14, 2007 and issued as U.S. Pat. No. 8,114,143 on Feb. 14, 2012, which is related to, claims the priority benefit of, and is a divisional application of, U.S. patent application Ser. No. 10/782,149, filed Feb. 19, 2004 and issued as U.S. Pat. No. 7,454,244 on Nov. 18, 2008, which is related to, claims the priority benefit of, U.S. Provisional patent application No. 60/449,266, filed Feb. 21, 2003, U.S. Provisional patent application No. 60/493,145, filed Aug. 7, 2003, and U.S. Provisional Patent Application No. 60/502,139, filed Sep. 11, 2003. The contents of each of these applications are hereby incorporated by reference in their entirety into this disclosure.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3896373 | Zelby | Jul 1975 | A |
| 3986373 | Goodlaxson | Oct 1976 | A |
| 4327723 | Frankhouser | May 1982 | A |
| 4365639 | Goldreyer | Dec 1982 | A |
| 4380237 | Newbower | Apr 1983 | A |
| 4417886 | Frankhouser et al. | Nov 1983 | A |
| 4562843 | Djordjevich et al. | Jan 1986 | A |
| 4587975 | Salo et al. | May 1986 | A |
| 4644960 | Johans | Feb 1987 | A |
| 4660571 | Hess et al. | Apr 1987 | A |
| 4840182 | Carlson | Jun 1989 | A |
| 4841977 | Griffith et al. | Jun 1989 | A |
| 4873987 | Djordjevich et al. | Oct 1989 | A |
| 4899759 | Pederson | Feb 1990 | A |
| 4911174 | Pederson et al. | Mar 1990 | A |
| 4957110 | Vogel et al. | Sep 1990 | A |
| 5004456 | Botterbusch et al. | Apr 1991 | A |
| 5058583 | Geddes et al. | Oct 1991 | A |
| 5078678 | Katims | Jan 1992 | A |
| 5121750 | Katims | Jun 1992 | A |
| 5125410 | Misono et al. | Jun 1992 | A |
| 5174299 | Nelson | Dec 1992 | A |
| 5205830 | Dassa et al. | Apr 1993 | A |
| 5233994 | Shmulewitz | Aug 1993 | A |
| 5243995 | Maier | Sep 1993 | A |
| 5246426 | Lewis et al. | Sep 1993 | A |
| 5275162 | Edwards et al. | Jan 1994 | A |
| 5366443 | Eggers et al. | Nov 1994 | A |
| 5417208 | Winkler | May 1995 | A |
| 5453576 | Krivitski | Sep 1995 | A |
| 5522880 | Barone et al. | Jun 1996 | A |
| 5536248 | Weaver et al. | Jul 1996 | A |
| 5555618 | Winkler | Sep 1996 | A |
| 5599299 | Weaver et al. | Feb 1997 | A |
| 5603333 | Konings | Feb 1997 | A |
| 5634465 | Schmiesing et al. | Jun 1997 | A |
| 5665103 | Lafontaine et al. | Sep 1997 | A |
| 5702433 | Taylor et al. | Dec 1997 | A |
| 5769786 | Wiegel | Jun 1998 | A |
| RE35924 | Winkler | Oct 1998 | E |
| 5827192 | Gopakumaran et al. | Oct 1998 | A |
| 5836875 | Webster, Jr. | Nov 1998 | A |
| 5842998 | Gopakumaran et al. | Dec 1998 | A |
| 5971933 | Gopakumaran et al. | Oct 1999 | A |
| 6011988 | Lynch et al. | Jan 2000 | A |
| 6080149 | Huang et al. | Jun 2000 | A |
| 6081737 | Shah | Jun 2000 | A |
| 6112115 | Feldman et al. | Aug 2000 | A |
| 6165977 | Mochly-Rosen | Dec 2000 | A |
| 6187744 | Rooney | Feb 2001 | B1 |
| 6190370 | Tsui | Feb 2001 | B1 |
| 6191136 | Marban | Feb 2001 | B1 |
| 6231518 | Grabek et al. | May 2001 | B1 |
| 6233994 | Roy et al. | May 2001 | B1 |
| 6258035 | Hoeksel et al. | Jul 2001 | B1 |
| 6270493 | Lalonde et al. | Aug 2001 | B1 |
| 6273855 | Schmid et al. | Aug 2001 | B1 |
| 6287260 | Hascoet et al. | Sep 2001 | B1 |
| 6324416 | Seibert | Nov 2001 | B1 |
| 6325762 | Tjin | Dec 2001 | B1 |
| 6354999 | Dgany et al. | Mar 2002 | B1 |
| 6360123 | Kimchi et al. | Mar 2002 | B1 |
| 6398738 | Millar | Jun 2002 | B1 |
| 6406422 | Landesberg | Jun 2002 | B1 |
| 6456874 | Hafer et al. | Sep 2002 | B1 |
| 6471656 | Shalman et al. | Oct 2002 | B1 |
| 6471658 | Daniels et al. | Oct 2002 | B1 |
| 6477402 | Lynch et al. | Nov 2002 | B1 |
| 6494832 | Feldman et al. | Dec 2002 | B1 |
| 6503202 | Hossack et al. | Jan 2003 | B1 |
| 6506159 | Hascoet et al. | Jan 2003 | B2 |
| 6511413 | Landesberg | Jan 2003 | B2 |
| 6514226 | Levin et al. | Feb 2003 | B1 |
| 6545678 | Ohazama | Apr 2003 | B1 |
| 6569103 | Hoeksel et al. | May 2003 | B2 |
| 6569862 | Marban | May 2003 | B1 |
| 6652505 | Tsugita | Nov 2003 | B1 |
| 6663661 | Boneau | Dec 2003 | B2 |
| 6666828 | Greco et al. | Dec 2003 | B2 |
| 6711429 | Gilboa et al. | Mar 2004 | B1 |
| 6799064 | Hassett | Sep 2004 | B1 |
| 6887206 | Hoeksel et al. | May 2005 | B2 |
| 6905469 | Hascoet et al. | Jun 2005 | B2 |
| 6922579 | Taimisto et al. | Jul 2005 | B2 |
| 6926674 | Tenerz et al. | Aug 2005 | B2 |
| 6939313 | Saadat et al. | Sep 2005 | B2 |
| 6986744 | Krivitski | Jan 2006 | B1 |
| 7065403 | Mouchawar et al. | Jun 2006 | B1 |
| 7069072 | Jansen et al. | Jun 2006 | B2 |
| 7128734 | Wilson et al. | Oct 2006 | B1 |
| 7141019 | Pearlman | Nov 2006 | B2 |
| 7169107 | Jersey-Willuhn et al. | Jan 2007 | B2 |
| 7169109 | Jansen et al. | Jan 2007 | B2 |
| 7189205 | McMorrow et al. | Mar 2007 | B2 |
| 7189208 | Beatty et al. | Mar 2007 | B1 |
| 7236820 | Mabary et al. | Jun 2007 | B2 |
| 7270662 | Visram et al. | Sep 2007 | B2 |
| 7300430 | Wilson et al. | Nov 2007 | B2 |
| 7311702 | Tallarida et al. | Dec 2007 | B2 |
| 7326241 | Jang | Feb 2008 | B2 |
| 7381204 | Wilson et al. | Jun 2008 | B2 |
| 7454244 | Kassab et al. | Nov 2008 | B2 |
| 7519424 | Dennis et al. | Apr 2009 | B2 |
| 7599730 | Hunter et al. | Oct 2009 | B2 |
| 7601138 | Goebel et al. | Oct 2009 | B2 |
| 7616992 | Dennis et al. | Nov 2009 | B2 |
| 7627376 | Dennis et al. | Dec 2009 | B2 |
| 7697972 | Verard et al. | Apr 2010 | B2 |
| 7715925 | Hafer et al. | May 2010 | B2 |
| 7763196 | Goebel et al. | Jul 2010 | B2 |
| 7774055 | Min | Aug 2010 | B1 |
| 7775986 | Roeher et al. | Aug 2010 | B2 |
| 7833214 | Wilson et al. | Nov 2010 | B2 |
| 7846157 | Kozel | Dec 2010 | B2 |
| 7854740 | Carney | Dec 2010 | B2 |
| 7917193 | Crane | Mar 2011 | B2 |
| 7967782 | Laufer et al. | Jun 2011 | B2 |
| 8046052 | Verard et al. | Oct 2011 | B2 |
| 8060185 | Hunter et al. | Nov 2011 | B2 |
| 8078274 | Kassab | Dec 2011 | B2 |
| 8078279 | Dennis et al. | Dec 2011 | B2 |
| 8082032 | Kassab et al. | Dec 2011 | B2 |
| 8099161 | Kassab | Jan 2012 | B2 |
| 8114143 | Kassab et al. | Feb 2012 | B2 |
| 8133698 | Silver | Mar 2012 | B2 |
| 8185205 | Ben-David et al. | May 2012 | B2 |
| 8204582 | Zantos et al. | Jun 2012 | B2 |
| 8221402 | Francischelli et al. | Jul 2012 | B2 |
| 8241274 | Keogh et al. | Aug 2012 | B2 |
| 8244339 | Shen et al. | Aug 2012 | B2 |
| 8280477 | Lau et al. | Oct 2012 | B2 |
| 8303505 | Webler et al. | Nov 2012 | B2 |
| 8326419 | Rosenberg et al. | Dec 2012 | B2 |
| 8374689 | Gopinathan et al. | Feb 2013 | B2 |
| 8388541 | Messerly et al. | Mar 2013 | B2 |
| 8388546 | Rothenberg | Mar 2013 | B2 |
| 8401616 | Verard et al. | Mar 2013 | B2 |
| 8409103 | Grunwald et al. | Apr 2013 | B2 |
| 8494794 | Dutta et al. | Jul 2013 | B2 |
| 8521249 | O'Dea | Aug 2013 | B2 |
| 8597193 | Grunwald et al. | Dec 2013 | B2 |
| 8632469 | Kassab | Jan 2014 | B2 |
| 8798712 | Gopinathan et al. | Aug 2014 | B2 |
| 8825151 | Gopinathan et al. | Sep 2014 | B2 |
| 9006708 | Bennett et al. | Apr 2015 | B2 |
| 9066708 | Kassab | Jun 2015 | B2 |
| 10172538 | Kassab | Jan 2019 | B2 |
| 20010012934 | Chandrasekaran et al. | Aug 2001 | A1 |
| 20020049488 | Boneau | Apr 2002 | A1 |
| 20020087089 | Ben-Haim | Jul 2002 | A1 |
| 20020129952 | Matsudate et al. | Sep 2002 | A1 |
| 20020165537 | Kelley et al. | Nov 2002 | A1 |
| 20020177783 | Khalil | Nov 2002 | A1 |
| 20030013986 | Saadat | Jan 2003 | A1 |
| 20030130711 | Pearson et al. | Jul 2003 | A1 |
| 20030149368 | Hennemann et al. | Aug 2003 | A1 |
| 20030163128 | Patil et al. | Aug 2003 | A1 |
| 20030171894 | Giovanni Battista Mancini et al. | Sep 2003 | A1 |
| 20030195433 | Turovskiy et al. | Oct 2003 | A1 |
| 20040019447 | Shachar | Jan 2004 | A1 |
| 20040024329 | Jansen et al. | Feb 2004 | A1 |
| 20040116816 | Tenerz et al. | Jun 2004 | A1 |
| 20040122421 | Wood | Jun 2004 | A1 |
| 20040220562 | Garabedian et al. | Nov 2004 | A1 |
| 20040230131 | Kassab et al. | Nov 2004 | A1 |
| 20040243116 | Joye et al. | Dec 2004 | A1 |
| 20040254495 | Mabary et al. | Dec 2004 | A1 |
| 20050010110 | Black et al. | Jan 2005 | A1 |
| 20050096647 | Steinke et al. | May 2005 | A1 |
| 20050119647 | He et al. | Jun 2005 | A1 |
| 20050240147 | Makower et al. | Oct 2005 | A1 |
| 20050256521 | Kozel | Nov 2005 | A1 |
| 20060009759 | Chrisitian et al. | Jan 2006 | A1 |
| 20060116633 | Shachar | Jun 2006 | A1 |
| 20060149166 | Zvuloni | Jul 2006 | A1 |
| 20060173251 | Govari et al. | Aug 2006 | A1 |
| 20060206106 | Scholl et al. | Sep 2006 | A1 |
| 20070016007 | Govari et al. | Jan 2007 | A1 |
| 20070016069 | Grunwald et al. | Jan 2007 | A1 |
| 20070016070 | Grunwald et al. | Jan 2007 | A1 |
| 20070016072 | Grunwald et al. | Jan 2007 | A1 |
| 20070062547 | Pappone | Mar 2007 | A1 |
| 20070083194 | Kunis et al. | Apr 2007 | A1 |
| 20070161914 | Zdeblick et al. | Jul 2007 | A1 |
| 20070232896 | Gilboa et al. | Oct 2007 | A1 |
| 20070255270 | Carney | Nov 2007 | A1 |
| 20080004652 | Abboud et al. | Jan 2008 | A1 |
| 20080033316 | Kassab et al. | Feb 2008 | A1 |
| 20080033350 | Wilson et al. | Feb 2008 | A1 |
| 20080176271 | Silver et al. | Jul 2008 | A1 |
| 20080188830 | Rosenblatt et al. | Aug 2008 | A1 |
| 20080190438 | Harlev et al. | Aug 2008 | A1 |
| 20080194996 | Kassab | Aug 2008 | A1 |
| 20080255475 | Kondrosky et al. | Oct 2008 | A1 |
| 20080269581 | Wood et al. | Oct 2008 | A1 |
| 20080269611 | Pedrizzetti et al. | Oct 2008 | A1 |
| 20080294041 | Kassab | Nov 2008 | A1 |
| 20080319350 | Wallace et al. | Dec 2008 | A1 |
| 20090005674 | Saadat et al. | Jan 2009 | A1 |
| 20090005675 | Grunwald et al. | Jan 2009 | A1 |
| 20090062664 | Chang et al. | Mar 2009 | A1 |
| 20090062684 | Gregersen et al. | Mar 2009 | A1 |
| 20090118612 | Grunwald et al. | May 2009 | A1 |
| 20090118637 | Kassab et al. | May 2009 | A1 |
| 20090143640 | Saadat et al. | Jun 2009 | A1 |
| 20090177090 | Grunwald et al. | Jul 2009 | A1 |
| 20090182287 | Kassab | Jul 2009 | A1 |
| 20090209872 | Pop | Aug 2009 | A1 |
| 20090209950 | Starksen | Aug 2009 | A1 |
| 20090216133 | Kassab | Aug 2009 | A1 |
| 20090259124 | Rothenberg | Oct 2009 | A1 |
| 20090262982 | Markowitz et al. | Oct 2009 | A1 |
| 20090262992 | Markowitz et al. | Oct 2009 | A1 |
| 20090264778 | Markowitz et al. | Oct 2009 | A1 |
| 20090270729 | Corbucci et al. | Oct 2009 | A1 |
| 20090270746 | Min | Oct 2009 | A1 |
| 20100010355 | Kassab | Jan 2010 | A1 |
| 20100010612 | Gelbart et al. | Jan 2010 | A1 |
| 20100036227 | Cox et al. | Feb 2010 | A1 |
| 20100041984 | Shapland et al. | Feb 2010 | A1 |
| 20100049062 | Ziv | Feb 2010 | A1 |
| 20100076328 | Matsumura et al. | Mar 2010 | A1 |
| 20100198346 | Keogh et al. | Aug 2010 | A1 |
| 20100210938 | Verard et al. | Aug 2010 | A1 |
| 20100222786 | Kassab | Sep 2010 | A1 |
| 20100268059 | Ryu et al. | Oct 2010 | A1 |
| 20100291521 | Simon | Nov 2010 | A1 |
| 20110015533 | Cox et al. | Jan 2011 | A1 |
| 20110034823 | Gelbart et al. | Feb 2011 | A1 |
| 20110196255 | Kassab | Aug 2011 | A1 |
| 20110245662 | Eggers et al. | Oct 2011 | A1 |
| 20110270237 | Werneth et al. | Nov 2011 | A1 |
| 20110306867 | Gopinathan et al. | Dec 2011 | A1 |
| 20120053441 | Kassab | Mar 2012 | A1 |
| 20120059249 | Verard et al. | Mar 2012 | A1 |
| 20120071782 | Patil et al. | Mar 2012 | A1 |
| 20120078342 | Vollkron et al. | Mar 2012 | A1 |
| 20120108950 | He et al. | May 2012 | A1 |
| 20120136242 | Qi et al. | May 2012 | A1 |
| 20120143029 | Silverstein et al. | Jun 2012 | A1 |
| 20120143078 | Kassab et al. | Jun 2012 | A1 |
| 20120169712 | Hill et al. | Jul 2012 | A1 |
| 20120172746 | Kassab | Jul 2012 | A1 |
| 20120226148 | Jaggi et al. | Sep 2012 | A1 |
| 20120302869 | Koyrakh et al. | Nov 2012 | A1 |
| 20130041269 | Stahmann et al. | Feb 2013 | A1 |
| 20130267835 | Edwards | Oct 2013 | A1 |
| 20130338468 | Kassab | Dec 2013 | A1 |
| 20140066738 | Kassab | Mar 2014 | A1 |
| 20150080762 | Kassab et al. | Mar 2015 | A1 |
| 20150297113 | Kassab et al. | Oct 2015 | A1 |
| 20190110844 | Misener et al. | Apr 2019 | A1 |
| 20190133489 | Kassab | May 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 102118994 | Jul 2011 | CN |
| 0486979 | May 1992 | EP |
| 0596344 | May 1994 | EP |
| 0786266 | Jul 1997 | EP |
| 0988827 | Mar 2000 | EP |
| 1025805 | Aug 2000 | EP |
| 2061532 | May 2009 | EP |
| 2134403 | Dec 2009 | EP |
| 1998035611 | Aug 1998 | WO |
| 2002019905 | Mar 2002 | WO |
| 2002085442 | Oct 2002 | WO |
| 2003092495 | Nov 2003 | WO |
| 2004004828 | Jan 2004 | WO |
| 2004075928 | Sep 2004 | WO |
| 2006005985 | Jan 2006 | WO |
| 2007015239 | Feb 2007 | WO |
| 2008000833 | Jan 2008 | WO |
| 2008031821 | Mar 2008 | WO |
| 2008126074 | Oct 2008 | WO |
| 2009003138 | Dec 2008 | WO |
| 2010124169 | Oct 2010 | WO |
| 2010130723 | Nov 2010 | WO |
| 2011023911 | Mar 2011 | WO |
| 2011024961 | Mar 2011 | WO |
| 2011026337 | Mar 2011 | WO |
| 2012110955 | Aug 2012 | WO |
| 2012173697 | Dec 2012 | WO |
| 2013152335 | Oct 2013 | WO |
| 2016040394 | Mar 2016 | WO |
| Entry |
|---|
| AU 2013243252 filed Aug. 13, 2014 Examination Report dated Nov. 9, 2016. |
| AU 2013243252 filed Aug. 13, 2014 Notice of Acceptance dated Mar. 23, 2017. |
| CN 201380018999.6 filed Oct. 8, 2014 Office Action dated Aug. 30, 2016. |
| CN 201380018999.6 filed Oct. 8, 2014 Office Action dated Mar. 30, 2017. |
| CO 14.244.362 filed Nov. 5, 2016 Office Action dated Jan. 23, 2017. |
| CO 14.244.362 filed Nov. 5, 2016 Office Action dated Nov. 7, 2016. |
| MX/a/2014/011884 filed Oct. 1, 2014 Office Action dated Jan. 30, 2017. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Advisory Action dated Jan. 25, 2017. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Final Office Action dated Nov. 17, 2016. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Advisory Action dated Oct. 12, 2016. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Final Office Action dated Mar. 29, 2017. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Non-Final Office Action dated Dec. 15, 2016. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Advisory Action dated Oct. 31, 2016. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Non-Final Office Action dated Dec. 22, 2016. |
| U.S. Appl. No. 141/52,697, filed Jun. 26, 2015 Non-Final Office Action dated Feb. 7, 2017. |
| MX/a/2014/011884 filed Oct. 1, 2014 Office Action dated Oct. 3, 2017. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Advisory Action dated Jan. 17, 2018. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Final Office Action dated Oct. 30, 2017. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Non-Final Office Action dated Jul. 7, 2017. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Advisory Action dated Jun. 20, 2017. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Non-Final Office Action dated Dec. 29, 2017. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Advisory Action dated Sep. 13, 2017. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Final Office Action dated Jun. 21, 2017. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Non-Final Action dated Dec. 11, 2017. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Advisory Action dated Oct. 6, 2017. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Final Office Action dated Jul. 21, 2017. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Non-Final Office Action dated Jan. 31, 2018. |
| U.S. Appl. No. 14/848,331, filed Sep. 8, 2015 Restriction Requirement dated Nov. 22, 2017. |
| CO 14244362 filed Nov. 5, 2016 Office Action dated Feb. 5, 2018. |
| MX/a/2014/011884 filed Oct. 1, 2014 Office Action dated Feb. 20, 2018. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Non-Final Action dated Feb. 28, 2018. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Advisory Action dated Jul. 24, 2018. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Final Action dated May 8, 2018. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Final Office Action dated Jul. 24, 2018. |
| U.S. Appl. No. 14/848,331, filed Sep. 8, 2015 Non-Final Office Action dated Feb. 6, 2018. |
| U.S. Appl. No. 14/848,331, filed Sep. 8, 2015 Notice of Allowance dated Aug. 1, 2018. |
| Cn 201380018999.6 filed Oct. 8, 2014 First Office Action dated Feb. 14, 2016. |
| Douglas A. Hettrick, et al. “Finite Element Model Determination of . . . ” Annals of Biomedical Engineering. vol. 27, pp. 151-159, 1999. |
| Douglas A. Hettrick, et al. “In Vivo Measurement of Real-Time Aortic Segmental Volume . . . ” Annals of Biomedical Engineering. vol. 26, pp. 431-440, 1998. |
| EP 13772981.0 filed Apr. 5, 2013 Extended European Search Report dated Oct. 14, 2015. |
| Hoekstein and Inbar, “Cardiac Stroke Volume Estimation . . . ” Technion Department of Electrical Engineering Publication EE PUB No. 991, Feb. 1994. |
| International Searching Authority, International Preliminary Report on Patentability, PCT/US1 0/32178, dated Nov. 3, 2011. |
| International Searching Authority, PCT Search Report and Written Opinion, PCT/US04/04828, dated Jul. 5, 2005. |
| International Searching Authority, PCT Search Report and Written Opinion, PCT/US06/05985, dated Aug. 8, 2007. |
| International Searching Authority, PCT Search Report and Written Opinion, PCT/US11/23911, dated Apr. 4, 2011. |
| International Searching Authority, PCT Search Report and Written Opinion, PCT/US11/24961, dated Aug. 30, 2012. |
| International Searching Authority, PCT Search Report and Written Opinion, PCT/US11/26337, dated Sep. 7, 2012. |
| Konings, M. K. et al. “Correct positioning of central venous catheters using a new electric method,” J Vasc Access Mar. 9, 2015; 16 (4): 327-332. |
| L. Komet, et al. “Conductance Method for the Measurement of . . . ” Annals of Biomedical Engineering, vol. 27. pp. 141-150, 1999. |
| PCT/US07/15239 filed Jun. 29, 2007 International Search Report dated Jun. 5, 2008. |
| PCT/US2008/000833 filed Jan. 23, 2008 International Search Report dated Nov. 6, 2008. |
| PCT/US2013/035527 filed Apr. 5, 2013 International Preliminary Report on Patentability dated Oct. 16, 2014. |
| PCT/US2015/049043 filed Sep. 8, 2015 International Search Report and Written Opinion dated Feb. 1, 2016. |
| Supplementary European Search Report for EP Application Serial No. 04 71 2383 to Electro-Cat, LLC, dated Aug. 6, 2007. |
| Svendsen, Mark C. et al., “Accurate nonfluoroscopic guidance and tip location of peripherally inserted central catheters using a conductance guidewire system,” Journal of Vascular Surgery: Venous and Lymphatic Disorders, vol. 1, Issue 2, pp. 202-208. (Jan. 5, 2013). |
| U.S. Appl. No. 14/010,139, filed Aug. 26, 2013 Advisory Action dated Oct. 29, 2015. |
| U.S. Appl. No. 14/010,139, filed Aug. 26, 2013 Final Office Action dated Aug. 20, 2015. |
| U.S. Appl. No. 14/010,139, filed Aug. 26, 2013 Non-Final Office Action dated Dec. 15, 2015. |
| U.S. Appl. No. 14/010,139, filed Aug. 26, 2013 Non-Final Office Action dated Mar. 26, 2015. |
| U.S. Appl. No. 14/010,139, filed Aug. 26, 2013 Notice of Allowance dated May 20, 2016. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Advisory Action dated Jun. 7, 2016. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Final Office Action dated Mar. 22, 2016. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Non-Final Office Action dated Aug. 18, 2016. |
| U.S. Appl. No. 14/010,169, filed Aug. 26, 2013 Non-Final Office Action dated Dec. 7, 2015. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Final Office Action dated Jul. 26, 2016. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Non-Final Office Action dated Apr. 15, 2016. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Non-Final Office Action dated Jan. 13, 2016. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Final Office Action dated Aug. 16, 2016. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Non-Final Office Action dated Feb. 24, 2016. |
| CA 2864860 filed Aug. 15, 2014 Office Action dated Jan. 30, 2019. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Advisory Action dated Nov. 28, 2018. |
| U.S. Appl. No. 14/010,202, filed Aug. 26, 2013 Notice of Allowance dated May 15, 2019. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Final Office Action dated Apr. 15, 2019. |
| U.S. Appl. No. 14/394,204, filed Oct. 13, 2014 Non-Final Office Action dated Nov. 20, 2018. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Advisory Action dated Oct. 9, 2018. |
| U.S. Appl. No. 14/752,697, filed Jun. 26, 2015 Non-Final Office Action dated Mar. 12, 2019. |
| Number | Date | Country | |
|---|---|---|---|
| 20170071501 A1 | Mar 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60502139 | Sep 2003 | US | |
| 60493145 | Aug 2003 | US | |
| 60449266 | Feb 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10782149 | Feb 2004 | US |
| Child | 11891981 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14010139 | Aug 2013 | US |
| Child | 15269767 | US | |
| Parent | 13324222 | Dec 2011 | US |
| Child | 14010139 | US | |
| Parent | 12098242 | Apr 2008 | US |
| Child | 13324222 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11891981 | Aug 2007 | US |
| Child | 12098242 | US |
